InvestorsHub Logo
Followers 41
Posts 1440
Boards Moderated 0
Alias Born 04/05/2009

Re: jmh0602 post# 2673

Friday, 01/20/2017 1:33:03 PM

Friday, January 20, 2017 1:33:03 PM

Post# of 3833
I will opine on the combination therapy. There is a drug called DAVANAT - GM-CT-01 that went through THREE phase II studies before Traber took the help. Each study showed efficacy BUT the trial design sucked so they weren't able to show statistical relevance. So whats new - a botched psoriasis trial and a completely useless FX trial. Now the Providence trial had nothing to do with GALT. So you have to be positive based on that fact alone but the market believes that the same inept CMO is presenting when that is not the case. That's the market disconnect.

Back to the history. DAVANAT in combination with AVASTIN made AVASTIN - SAFE. So everyone who took AVASTIN and had to deal with the side effects I feel for the patients when the study proved that the SAE when mixed with DAVANAT were eliminated. The reason they didn't move forward with a follow on study was all about the greenbacks. AVASTIN is a very expensive drug and to do the trial was going to be very costly and why would Genentech want to make AVASTIN safer when they sell all the side effect drugs to boost blood counts. So does it work - very much so but they have to prove that to the medical community. The scientific community can't look at the fact that it worked really well on colon cancer, worked on breast cancer, worked on bile duct cancer, worked with AVASTIN. The scientists demand that it works with statistical relevance higher than the current standard of care. Until they prove that they are in purgatory. It really looks like this Providence presentation is going to blow us all away and shock everyone but it shouldn't shock any of us here because you just look at the trail of evidence of it working over and over again then you look at the science and how the Galectin 3 is responsible for all bad diseases and this blocks it. So why on earth wouldn't it work.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News